Serum IL-33/ST2 Axis Expression in Acute Exacerbations of COPD: Correlation with Pulmonary Function

Area of Science:

• Pulmonary Medicine
• Biomarker Research
• Respiratory Diseases

Background:

• Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are major contributors to patient morbidity and mortality.
• Effective COPD management relies on identifying biomarkers associated with disease severity.
• This study focuses on serum interleukin-33 (IL-33) and soluble ST2 (ST2) levels in relation to pulmonary function during AECOPD.

Purpose of the Study:

• To investigate the association between serum IL-33 and ST2 levels and reduced pulmonary function in AECOPD patients.
• To explore the impact of these biomarkers across different patient subgroups, including age, gender, and pulmonary hypertension.
• To determine the potential of IL-33 and ST2 as predictive biomarkers for pulmonary function decline in AECOPD.

Main Methods:

• Cross-sectional analysis of 194 patients diagnosed with AECOPD.
• Measurement of serum IL-33 and ST2 levels.
• Assessment of pulmonary function parameters, including FEV1% predicted and FEV1/FVC ratio.
• Stratification of patients into subgroups based on age, gender, and presence of pulmonary hypertension (PH).
• Statistical analysis using correlation and logistic regression models.

Main Results:

• Significant inverse correlations were observed between serum IL-33 and ST2 levels and FEV1% predicted (IL-33: r = -0.561; ST2: r = -0.545) and FEV1/FVC ratio (p < 0.001).
• Logistic regression indicated that higher IL-33 (OR = 1.32) and ST2 (OR = 1.29) levels were associated with reduced pulmonary function (p < 0.001).
• Subgroup analyses revealed stronger associations in older patients (≥ 67 years), males, and individuals with PH.

Conclusions:

• Serum IL-33 and ST2 are identified as promising biomarkers for predicting reduced pulmonary function in AECOPD.
• The predictive utility of these biomarkers is particularly notable in specific demographic groups.
• Findings underscore the importance of integrating biomarker-based strategies into COPD management for risk stratification and personalized care.